Methyldopa Accord-Uk

Methyldopa, the active ingredient in Methyldopa Accord-Uk, is a centrally acting alpha-2 adrenergic agonist presented as an oral tablet for oral use. It lowers elevated blood pressure in adults, including those with pregnancy‑induced hypertension.

GNH USA supplies Methyldopa Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements.

Methyldopa is used to manage hypertension and related conditions by acting on central sympathetic pathways.

Hypertension: reduces systolic and diastolic blood pressure in adult patients. Pregnancy‑induced hypertension: controls blood pressure safely during gestation. Essential hypertension: provides long‑term blood pressure control when other agents are unsuitable.

Methyldopa may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Dry mouth - Nausea - Constipation

Serious or Rare Side Effects: - Hepatic dysfunction - Hemolytic anemia - Severe hypotension - Stevens‑Johnson syndrome - Agranulocytosis - Lupus‑like syndrome

When prescribing methyldopa, clinicians should observe several safety considerations.

Monitor blood pressure regularly: adjust dose to maintain target levels. Renal impairment: use caution and consider dose reduction. Hepatic disease: avoid or use with close monitoring. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Pregnancy category B: generally considered safe, but use under medical supervision. Store at below 25°C: keep in the original pack, protect from moisture.

Methyldopa can interact with other medicines, altering its antihypertensive effect or increasing toxicity.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of severe hypertension. - Other central alpha‑2 agonists (e.g., clonidine): additive hypotensive effect. - Tricyclic antidepressants: may blunt antihypertensive response.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may reduce antihypertensive efficacy. - Diuretics: increase risk of electrolyte imbalance. - Insulin or oral hypoglycemics: may enhance hypoglycemic effect.